Report

The FY2024 Capacity Assessment Check In is part of the Department of Health and Human Services’ (HHS) multi-year approach for addressing the primary capacity building needs identified through the initial FY2023-2026 HHS Capacity Assessment.

Prior research from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) and U.S. Department of Housing and Urban Development (HUD) Office of Policy Development and Research (PD&R) show older adults receiving federal housing assistance face disproportionately high rates of chronic conditions and health care utilization.

The 2023 Office of the Secretary Patient-Centered Outcomes Research Trust Fund (OS-PCORTF) Annual Report highlights the accomplishments of 36 multi-agency projects that supports the four goals of the strategic plan:

The calculation of behavioral health quality measures at the clinic level holds great promise for monitoring clinic performance over time, and for providing information for clinics to use to revise their processes and procedures to improve their performance.

Patient navigation provides support and information to patients and their families to help navigate the complexities of health care services. These programs or services may include providing support and resources to inform clinical patient choices, financial responsibilities, and available social and community services.

Drug shortages are a persistent problem that can cause substantial disruption in patient treatment regimens and adversely impact a patient’s health. Drug shortages can have severe consequences for patients, including high costs, delayed care, and potential medication errors or unintended side effects when using alternative or unfamiliar drugs.

Executive Orders No. 13985 (2021) and 14091 (2023) require federal agencies to ensure that their policies and services, including data collection, advance equitable outcomes for all populations. The Assistant Secretary for Planning and Evaluation (ASPE) and the U.S.

This report does not represent the views or policies of the Department of Health and Human Services or the Trump Administration. It was published in 2024 and is provided only for historical purposes.

ASPE contracted with RAND Health Care to carry out three studies analyzing data on U.S. prescription drug prices and availability in comparison to drug prices and availability in other Organisation for Economic Co-operation and Development (OECD) countries. In 2022, U.S. prices across all drugs (brands and generics) were nearly 2.78 times as high as prices in the comparison countries. U.S.

Provider directories are lists of in-network providers produced by health care plans. They are an important tool for individuals seeking health care providers, and for regulators who monitor the adequacy of health plans’ provider networks.